Home › Juvenile Myelomonocytic Leukemia › Illinois › Chicago
Juvenile Myelomonocytic Leukemia clinical trials in Chicago, IL
3 studies for Juvenile Myelomonocytic Leukemia are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
RecruitingPhase 1/2
- Lurie Children's Hospital of Chicago, Chicago
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
RecruitingPhase 1
- Lurie Children's Hospital-Chicago, Chicago
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Juvenile Myelomonocytic Leukemia trials in other cities
- Philadelphia, PA4 studies
- Minneapolis, MN4 studies
- Boston, MA3 studies
- Seattle, WA3 studies
- Cincinnati, OH3 studies
- Washington, DC3 studies
- Atlanta, GA3 studies
- New York City, NY3 studies
- Indianapolis, IN3 studies
- San Francisco, CA3 studies
- Ann Arbor, MI3 studies
- Memphis, TN3 studies
Other studies in Chicago
- Non-Small Cell Lung Cancer61 studies
- Breast Cancer58 studies
- Cancer (all types)51 studies
- Metastatic Cancer45 studies
- Prostate Cancer45 studies
- Obesity41 studies
- Lung Cancer41 studies
- Ovarian Cancer36 studies
- Stroke34 studies
- Colorectal Cancer33 studies
- Heart Failure31 studies
- Overweight28 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.